In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Lilly to Buy Scorpion’s PI3Kα Inhibitor for Breast Cancer Eli Lilly announced that it is ... being developed in a phase I/II study for breast cancer and other advanced solid tumors.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...